2025年11月14日,EMA发布了一项具有里程碑意义的积极意见:推荐批准Teizelid(活性成分:teplizumab)在欧盟上市,用于延迟8岁及以上2期1型糖尿病患者进展至3期1型糖尿病。这不仅标志着首款能够干预1型糖尿病自然病程的药物在欧洲获得认可,更意味着数百万患者——尤其是儿童,有望迎来一个不再被胰岛素依赖所定义的未来。1型糖尿病是一种慢性自身免疫性疾病,患者的免疫系统错误地攻击并破坏...
Source Link2025年11月14日,EMA发布了一项具有里程碑意义的积极意见:推荐批准Teizelid(活性成分:teplizumab)在欧盟上市,用于延迟8岁及以上2期1型糖尿病患者进展至3期1型糖尿病。这不仅标志着首款能够干预1型糖尿病自然病程的药物在欧洲获得认可,更意味着数百万患者——尤其是儿童,有望迎来一个不再被胰岛素依赖所定义的未来。1型糖尿病是一种慢性自身免疫性疾病,患者的免疫系统错误地攻击并破坏...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.